India's Pharma Giants Are Quietly Using AI — And It's Changing Everything
Something remarkable is happening inside India's pharmaceutical boardrooms. Quietly, methodically, and with growing urgency, the country's biggest drug makers are embedding artificial intelligence into every layer of their operations from the molecular laboratories where new medicines are born, to the warehouses where they are packed and shipped. As reported by The Economic Times, India's drug giants are now betting big on artificial intelligence, and the transformation underway is nothing short of extraordinary.
India: The Pharmacy of the World, Now Powered by Algorithms
India's pharmaceutical industry has long earned its title as the "pharmacy of the world." With over 3,000 pharmaceutical companies, approximately 10,500 manufacturing units, and the distinction of being the largest provider of generic medicines globally, this is a sector built on scale, affordability, and reliability. India accounts for 20% of global generic drug exports and produces 60% of the world's vaccines. Yet, despite this commanding presence, the industry has recognised that resting on its generics reputation is no longer sufficient. The next great leap must be driven by innovation — and artificial intelligence is the vehicle chosen to make that journey. This ambition is deeply connected to India's broader national AI push, which has been gaining serious momentum since the government launched its AI Mission Portal, a game-changing initiative designed to accelerate AI adoption across key sectors of the economy.
IndiaOnAi.com
Premium domain for sale, ideal for AI startups and innovation-driven businesses
The traditional path to developing a new drug is brutally slow and expensive. On average, it takes over 14 years and costs around $2.6 billion to bring a single medicine from a laboratory to a patient's bedside. Failure rates along the way are staggering. AI is now changing these odds dramatically. By analysing vast amounts of biological data, predicting molecular interactions, and running virtual simulations at speeds no human researcher could match, AI is compressing timelines and reducing costs in ways that were simply unimaginable a decade ago. For India's pharma firms — many of which have historically invested just 5–8% of revenue in research — the pressure to scale up innovation has never been greater. AI offers them a way to punch far above their weight class.
Sun Pharma and Glenmark Lead the Charge
Among India's pharma heavyweights, Sun Pharmaceutical Industries and Glenmark Pharmaceuticals have emerged as some of the most vocal advocates for AI-powered drug development. Sun Pharma's Executive Chairman, Dilip Shanghvi, has stressed the critical need to harness AI across the drug development pipeline — from recruiting patients for clinical trials to accelerating regulatory submissions. According to Whalesbook, Shanghvi believes AI could shave as much as 1.5 years off the drug development process — a massive saving in both time and capital. Glenmark's Chairman, Glenn Saldanha, similarly sees AI as central to the entire research cycle, particularly in analysing clinical trial data and speeding up filings with regulators.
Dr. Reddy's: Turning AI Into a Competitive Weapon
Dr. Reddy's Laboratories has gone a step further, launching its own AI-assisted drug discovery platform called Aurigene.AI. This platform has already demonstrated impressive results, achieving a 35% reduction in the cycle time for the critical steps of chemical design, synthesis, and testing. This means faster identification of viable drug candidates, fewer failed experiments, and ultimately a quicker path to clinical trials. Dr. Reddy's approach signals a broader shift across the industry — from cautious experimentation with AI tools to active, full-scale deployment as a competitive differentiator. The company is proving that AI in pharma is not just a buzzword; it is a business strategy with measurable returns.
Half of India's Pharma Firms Are Already Exploring AI
The AI push is not limited to the headline names. Across India's pharmaceutical landscape, the numbers tell a striking story. Approximately 50% of Indian pharma firms are actively exploring generative AI proof-of-concept initiatives, while around a quarter have already implemented AI solutions in live production environments. Industry experts have noted that 2026 marks a decisive shift — from a period of experimentation and pilot projects to one of scaled, enterprise-wide AI adoption. As Suresh Subramanian, National Lifesciences Leader at EY Parthenon India, put it, the winners in this new era will be those who integrate discovery, AI-native intelligence, and manufacturing into disciplined, repeatable platforms — not those who treat AI as a one-off add-on. It is worth noting that this wave of AI adoption in pharma is happening alongside a broader national story: Indian AI companies like Sarvam AI, which is set to hit unicorn status, are demonstrating that India has both the homegrown talent and the technological ambition to compete at the very highest levels of AI innovation globally.
Molecule Screening: Finding Needles in a Biological Haystack
Perhaps the most transformative application of AI in Indian pharma is in molecule screening and drug discovery. Traditionally, scientists would spend years manually testing thousands of compounds to find even a handful worth pursuing further. AI changes this equation entirely. Machine learning models can now virtually screen millions of molecules, predict their interactions with human proteins, and flag those most likely to be safe and effective — all before a single test tube is touched. Companies like Laurus Labs are already using AI to optimise chemical synthesis routes, reducing both waste and cost. Peptris, another innovative player, is using similar tools to screen for potential toxicity in silico, dramatically cutting the failure rate in actual wet lab experiments.
AI in Manufacturing: Smarter Factories, Fewer Defects
Beyond the research laboratory, AI is reshaping how drugs are actually manufactured. Computer vision systems are being deployed on production lines to detect anomalies in tablets and packaging with a level of precision no human inspector could sustain across an eight-hour shift. Predictive maintenance tools continuously monitor the health of manufacturing equipment, flagging potential breakdowns before they cause costly production halts. These technologies are not just improving product quality; they are helping Indian manufacturers maintain the rigorous compliance standards demanded by global regulators such as the US Food and Drug Administration. As USFDA inspections of Indian plants have sharply rebounded in 2024 and 2025, the ability to demonstrate AI-powered quality control is becoming a real competitive advantage.
Personalised Medicine: AI Meets Genomics
One of the most exciting frontiers being explored by Indian pharma and healthcare companies is the combination of AI with genomics to enable truly personalised medicine. The AI-driven precision medicine market in India is projected to reach $710.9 million by 2030, growing at a compound annual growth rate of 37.2%, according to Sify. AI-driven tools are being developed to help design personalised therapies, select appropriate dosages, and flag potential adverse drug reactions based on a patient's unique genetic profile. Apollo Cancer Centre has already launched India's first AI-Precision Oncology Centre, while Indian startups like MedMitra AI are building diagnostic platforms that bring these capabilities to a broader patient base. This is not the future of medicine — it is happening right now, in India.
Supply Chain Intelligence: Getting the Right Medicine to the Right Place
India's pharmaceutical supply chain is one of the most complex in the world, spanning a diverse and vast population, variable disease patterns across different regions, and the logistical challenge of reaching remote communities. AI-driven predictive analytics is now helping firms refine their inventory planning and production scheduling to a level of sophistication previously impossible. By analysing data from epidemiological reports, weather trends, regional demographic data, and pharmacy sales records, AI models generate remarkably accurate demand forecasts. This is especially critical for managing stock levels of essential medicines, where shortages can have serious consequences for public health. AI is also helping companies manage the seasonal spikes in demand — such as the surge in respiratory medicines during India's winter months or waterborne disease treatments during the monsoon season.
Government and Academia: Building the AI-Pharma Ecosystem
The ambitions of India's pharma sector are being supported by significant public investment. The Centre of Excellence for AI in Healthcare (AI-CoE), launched in 2025 as a collaboration between IIT Delhi and AIIMS Delhi, received funding of ₹330 crore to build indigenous AI solutions specifically designed to expand healthcare access for India's underserved communities. Additional AI Centres of Excellence are being established at AIIMS Rishikesh and PGIMER Chandigarh, creating a growing network of research hubs that will generate the data, talent, and tools Indian pharma companies need to scale their AI ambitions. India's biotech startup scene has also crossed 10,000 firms in 2025, with many focused squarely on AI-led drug discovery in oncology, infectious diseases, and neurology. Importantly, this AI revolution is not confined to large corporations alone — as explored in our coverage of how India's MSMEs are at the centre of the next AI wave, smaller enterprises are increasingly finding ways to plug into this technological transformation and benefit from it too.
RupeeAi.in
Acquisition Opportunity for Global & Indian Fintech AI Startups
For all the excitement, industry leaders are clear-eyed about the obstacles that remain. Joydeep Ghosh, Life Sciences & Healthcare Industry Leader at Deloitte India, has highlighted the fundamental challenge of data — not just quantity, but quality, granularity, and timeliness. India's healthcare data is fragmented across thousands of providers, laboratories, insurance companies, and pharmaceutical firms, making it enormously difficult to build AI models that are truly reliable at scale. There are also the challenges of integrating new AI tools with legacy manufacturing and IT systems, ensuring regulatory compliance as agencies like the USFDA develop their own AI guidance frameworks, and building a workforce capable of working effectively with these technologies. As Ghosh notes, the transition will most likely involve role evolution rather than mass job displacement — but reskilling will be essential.
The Global Market Opportunity: India Cannot Afford to Fall Behind
The financial stakes of getting this AI transition right are enormous. Globally, McKinsey estimates that generative AI could generate between $60 billion and $110 billion annually in economic value for the pharma and medical-products industries. The global AI in drug discovery market, valued at $1.8 billion in 2024, is expected to reach $14 billion by 2033, growing at a compound annual growth rate of 23.17%. Meanwhile, AI spending in the pharmaceutical sector globally is forecast to rise from $4 billion in 2025 to $25 billion by 2030. For India, which aspires to grow its pharmaceutical market from $55 billion today to $120–130 billion by 2030, embedding AI deeply across the value chain is not a nice-to-have. It is the path to relevance in the next era of global healthcare, according to the World Economic Forum.
From Generics to Genius: The Road Ahead
The story of AI in Indian pharma is ultimately a story of ambition — a country that built its pharmaceutical reputation on cost efficiency and scale, now reaching for something greater: original innovation. The transition will not happen overnight. Data gaps must be closed, workforces must be trained, and regulatory frameworks must evolve. But the direction is unmistakable. As one industry leader put it at the recent BioAsia 2026 conference in Hyderabad, embracing AI is no longer optional — it is the only way forward for an industry that wants to remain competitive in a world where every major pharmaceutical player is racing to harness intelligent technology. India's drug giants know this. And they are moving fast.
Source & AI Information: External links in this article are provided for informational reference to authoritative sources. This content was drafted with the assistance of Artificial Intelligence tools to ensure comprehensive coverage, and subsequently reviewed by a human editor prior to publication.
0 Comments